Rationale
Peak oxygen uptake (VO₂ max) is a key measure of cardiorespiratory fitness, yet its assessment typically requires maximal exertion testing with expensive equipment in a hospital setting. This limits routine monitoring and early detection of fitness-related health concerns, especially in children.
This study evaluates whether the Corsano CardioWatch 287-2B can accurately estimate peak VO₂ (pVO₂) during workouts performed via the Corsano app. Results will be compared with those from gold-standard hospital-based cardiopulmonary exercise tests (CPET).
If proven accurate, Corsano’s wearable could be used to monitor physical fitness in clinical and home settings, supporting pediatric rehabilitation, early intervention, and lifestyle monitoring.

Study Objectives
Primary Outcome
• Agreement between pVO₂ estimates from the Corsano app and maximal exertion CPET values in pediatric patients.

Secondary Outcome
• Feasibility and acceptability of app-based exercise protocols in children

Study Design
This is a prospective validation study. Each participant completes a standardized hospital-based maximal exercise test while also performing a Corsano-guided workout. Peak VO₂ estimates from both are compared for accuracy. Trained clinicians at the SHTC unit supervise all assessments.

Inclusion Criteria
• Children aged 6–17 years are eligible for VO₂ max testing
• Capable of understanding and completing both exercise tests
• Parental consent and child assent provided

Exclusion Criteria
• Medical contraindications to exertion testing
• Inability to wear the Corsano wristband

Current Status
As of now, 6 of 30 planned participants have been enrolled.

Timeline
Status: Recruiting patients.
Start Date: January 23, 2025
Expected Duration: 3–4 months (once resumed)
Target Sample Size: 30 children (with potential for expansion)

Study center
Erasmus Medical Center (EMC), Rotterdam, The Netherlands – SHTC Unit

Interested in our Trial Programme?

Corsano Cardiowatch Bracelets enable continuous monitoring with multiple algorithms. Corsano is working closely with cardiologists, scientists, hospitals, patients, and research organisations.  Scientific research demonstrates the legitimacy of Cardiowatch 287 algorithms. 

We are currently performing pilots with selected clients. Contact us if you want to know more!

Corsano CardioWatch is a wrist worn medical grade multi sensor bracelet to capture up to 19 vital parameters. Primary use cases are 24/7 continuous clinical trials and remote patient monitoring.  
 
The bracelet monitor offers flexibility to set data collection intervals by minute, by second or 25Hz, 32 Hz or 128 Hz. We measure Heart Rate, RR intervals, Breathing Rate, A-Fib detection, Skin Temperature, Activity and Sleep. SpO2, Core Body Temperature, ECG and Blood Pressure are in development.  
 
Clinical accuracy is paramount for us. In addition to third parties' algorithms, i.e. from Philips, we run our proprietary algorithms to realize superior data accuracy. Corsano technology has been clinically validated in major academic hospitals. The bracelet is manufactured under ISO 13485 and CE-MDR compliance. The process for FDA Clearance has started. 
 
Our end-to-end solution consists of light-weight and comfortable bracelets with a patient research portal. We have developed and produced over 200’000 devices. The Corsano platform has been optimized on connections, data buffers and battery life up to 15 days. We offer access to raw continuous high frequency data through API and cloud-to-cloud solutions. 
 

The founders of Corsano Health have over 100 years of experience in the Swiss Watch industry, with deep experience about ergonomic design and materials for wearables that are worn 24/7.